GLAMProject ID: 634928
Laser Multiplexed Biosensor
Total cost:EUR 4 835 584,25
EU contribution:EUR 4 835 584
Topic(s):PHC-10-2014 - Development of new diagnostic tools and technologies: in vitro devices, assays and platforms
Call for proposal:H2020-PHC-2014-two-stageSee other projects for this call
Funding scheme:RIA - Research and Innovation action
Differential cancer diagnosis takes place daily in clinical settings for a better monitoring of patient responses to existing treatments. However outcome of this diagnosis is today still poor. Moreover, current technology to measure biomarker levels is expensive and sophisticated.
Most cancer biomarker analysis use blood or biological tissues as the main source of material. These biopsies must be analyzed in specialized laboratories incurring in some limitations: high cost; specialized personnel and equipment; large amounts of biological material; long outcome delivery time; time consuming processes.
Therefore it exist a real need and urgency to have new diagnostic devices that provide diagnosis, prognosis, and monitoring data faster and with exquisite ultra-sensitivity on time to take the appropriate decisions to improve personalized diagnosis and therapy.
The aim of GLAM project is to provide an innovative device to fulfill these requirements using soluble biomarkers for personalized diagnosis and therapy monitoring.
Specifically we will design and develop a new diagnostic tool to detect biomarkers from biofluids obtained in a non-invasive manner, specifically focusing to urine and to genitourinary cancers, to help oncologist to take better treatment decisions, approaching personalized medicine.
GLAM will develop an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost. GLAM capitalizes on the unprecedented sensitivity achieved using laser microring resonators to detect key biomarkers in tumor development and treatment. Point of Care of the device will be carried out by preclinical and clinical sample analysis of genitourinary cancer patients to warrant personalized medicine.
Importantly the GLAM unique technology will make the device also usable with other biofluids and might also be used to help physicians with other biomarker driven.
EU contribution: EUR 692 632,50
CARRER DE LA INNOVACIO 2
EU contribution: EUR 491 125,50
CARRER BALDIRI REIXAC PLANTA 2A 10-12
EU contribution: EUR 817 885
7522 NB ENSCHEDE
EU contribution: EUR 323 625
Beit Hillel 3
67017 TEL AVIV-JAFFO
EU contribution: EUR 374 412,50
Avenue Franklin Roosevelt 50
EU contribution: EUR 574 275
AVINGUDA CARL FRIEDRICH GAUSS 3
EU contribution: EUR 283 316
GEERT GROOTEPLEIN NOORD 9
6525 EZ NIJMEGEN
EU contribution: EUR 467 700
OMLADINSKIH BRIGADA 86 P
EU contribution: EUR 400 812,50
Bain Square 5
EH54 7DQ Livingston
EU contribution: EUR 409 800
BOULEVARD GENERAL WAHIS 53